Vaccine Market by Technology, Type, End User, Disease Indication - Forecasts to 2019

The vaccines market is expected to reach $57,885.4 million by 2019 from $33,140.6 million in 2014, at a CAGR of 11.8%. The global vaccines market is categorized on the basis of type, technology, disease indication, end user, and geography. The preventive vaccines segment is expected to register the highest growth rate in the vaccines market, by type, during the forecast period. Its favorable growth is attributed to the rising prevalence of diseases and increasing number of government initiatives taken for immunization programs worldwide.

Major factors contributing to growth of the vaccines market include rising prevalence of diseases, increasing company investments in vaccine development, and rising initiatives by non-government organizations for vaccinations. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in November 2014, the U.K. government granted $2 billion (￡1.32 billion) to GAVI for the improvement of immunization programs in poor countries. The emerging markets of the Asian region have opened an array of opportunities for the vaccines market. However, low accessibility to vaccines in remote areas and stringent regulatory procedures are expected to restrain the growth of this market.


Apart from the comprehensive geographical and product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by the industry players over the last three years. In addition, the company profiles comprise the basic views on the key players in the vaccines market and the product portfolios, developments, and strategies adopted by the market players to maintain and increase their market shares in the near future. The above mentioned market research data, current market size, and forecast of the future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

‧ Market Penetration: Comprehensive information on product portfolios of the top players in the vaccines market. The report analyzes the vaccines market by type, technology, disease indication, end users, and geography
‧ Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the vaccines market
‧ Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the vaccines market
‧ Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various vaccines across geographies
‧ Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the vaccines market

TABLE OF CONTENTS

1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 23
1.5 LIMITATIONS 23
1.6 STAKEHOLDERS 23
2 RESEARCH METHODOLOGY 24
2.1 MARKET SIZE ESTIMATION 25
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 27
2.3 MARKET SHARE ESTIMATION 28
2.4 KEY DATA FROM SECONDARY SOURCES 29
2.5 KEY DATA FROM PRIMARY SOURCES 29
2.6 KEY INDUSTRY INSIGHTS 30
2.7 ASSUMPTIONS 30
3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 35
4.1 VACCINES MARKET HAS HIGH GROWTH POTENTIAL 35
4.2 VACCINES MARKET, BY TYPE 36
4.3 VACCINES MARKET, BY REGION 37
4.4 VACCINES MARKET, BY DISEASE INDICATION 38
4.5 VACCINES MARKET, BY END USER 39
4.6 LIFECYCLE ANALYSIS, BY REGION 40
5 MARKET OVERVIEW 41
5.1 INTRODUCTION 42
5.2 MARKET SEGMENTATION 42
5.2.1 VACCINES MARKET, BY TECHNOLOGY 42
5.2.2 VACCINES MARKET, BY TYPE 42
5.2.3 VACCINES MARKET, BY DISEASE INDICATION 43
5.2.4 VACCINES MARKET, BY END USER 43
5.2.5 VACCINES MARKET, BY REGION 44
?
5.3 MARKET DYNAMICS 45
5.3.1 DRIVERS 45
5.3.1.1 High prevalence of diseases 45
5.3.1.2 Rising government and nongovernment funding for vaccine development 46
5.3.1.3 Increasing investments by companies 46
5.3.1.4 Technological advancements 47
5.3.2 RESTRAINTS 48
5.3.2.1 Huge capital investments 48
5.3.2.2 Stringent regulatory procedures 48
5.3.3 OPPORTUNITIES 49
5.3.3.1 High growth prospects in emerging markets 49
5.3.3.2 Therapeutic vaccines 49
5.3.3.3 Adjuvant vaccines 50
5.3.4 CHALLENGES 51
5.3.4.1 Inadequate access to vaccines 51
5.3.4.2 Vaccine pricing 51
5.3.5 BURNING ISSUES 52
5.3.5.1 Failure of vaccines 52
6 INDUSTRY INSIGHTS 53
6.1 PORTER’S FIVE FORCES ANALYSIS 53
6.1.1 THREAT FROM NEW ENTRANTS 53
6.1.2 BARGAINING POWER OF SUPPLIERS 54
6.1.3 BARGAINING POWER OF BUYERS 54
6.1.4 INTENSITY OF COMPETITIVE RIVALRY 54
6.1.5 THREAT OF SUBSTITUTES 54
6.2 VALUE CHAIN ANALYSIS 54
6.3 SUPPLY CHAIN ANALYSIS 55
6.4 TECHNOLOGY TRENDS FOR ADJUVANTS 57
6.4.1 DRIVERS 57
6.4.1.1 Increasing Use of Adjuvants in Vaccine-preventable Diseases 57
6.4.1.2 Rising Government Investments 57
6.4.2 RESTRAINS 57
6.4.2.1 High Cost of Research 57
6.4.2.2 Regulatory Hurdles 58
6.4.3 OPPORTUNITIES 58
6.4.3.1 Combined Adjuvants 58
6.4.3.2 Vaccines for Young Children 58
6.4.3.3 Pandemic Diseases 58
6.4.4 CHALLENGES 58
6.4.4.1 Identification of Adjuvants 58
6.4.4.2 Technological Limitations 58
6.4.5 TRENDS 59
6.4.5.1 Collaborations 59
6.4.5.2 New Adjuvant Technologies 59
6.5 INVESTMENT ANALYSIS 61
6.6 REGULATORY LANDSCAPE 64
6.6.1 NORTH AMERICA 64
6.6.2 EUROPE 65
6.6.3 ASIA 65
6.6.4 ROW 66
6.7 PATENT ANALYSIS 66
6.8 KEY PIPELINE PRODUCTS 68
6.9 STRATEGIC BENCHMARKING 70
7 VACCINES MARKET, BY TECHNOLOGY 72
7.1 INTRODUCTION 73
7.2 SUBUNIT VACCINES 74
7.3 LIVE ATTENUATED VACCINES 77
7.4 CONJUGATE VACCINES 79
7.5 INACTIVATED VACCINES 81
7.6 RECOMBINANT VECTOR VACCINES 84
7.7 TOXOID VACCINES 87
7.8 SYNTHETIC VACCINES 89
7.9 DENDRITIC CELL VACCINES 93
8 VACCINES MARKET, BY TYPE 95
8.1 INTRODUCTION 96
8.2 PREVENTIVE VACCINES 97
8.3 THERAPEUTIC VACCINES 100
9 VACCINES MARKET, BY DISEASE INDICATION 103
9.1 INTRODUCTION 104
9.2 INFECTIOUS DISEASES 105
9.2.1 PNEUMOCOCCAL 108
9.2.2 INFLUENZA 109
9.2.3 DTP 109
9.2.4 HEPATITIS 109
9.2.5 ROTAVIRUS 110
9.2.6 VARICELLA 110
9.2.7 MENINGOCOCCAL 110
9.2.8 POLIO 111
9.2.9 MMR 111
9.2.10 OTHERS 112
9.3 CANCER 112
9.3.1 CERVICAL CANCER 115
9.3.2 OTHER CANCERS 115
9.4 ALLERGIES 116
10 VACCINES MARKET, BY END USER 119
10.1 INTRODUCTION 120
10.2 PEDIATRICS 121
10.3 ADULTS 124
11 GLOBAL VACCINES MARKET, BY REGION 127
11.1 INTRODUCTION 128
11.2 NORTH AMERICA 131
11.2.1 U.S. 133
11.2.2 CANADA 136
11.3 EUROPE 138
11.3.1 GERMANY 141
11.3.2 FRANCE 145
11.3.3 U.K. 147
11.3.4 ITALY 149
11.3.5 SPAIN 151
11.3.6 REST OF EUROPE (ROE) 153
11.4 ASIA 155
11.4.1 JAPAN 158
11.4.2 CHINA 160
11.4.3 INDIA 163
11.4.4 REST OF ASIA (ROA) 165
11.5 REST OF THE WORLD (ROW) 167
12 COMPETITIVE LANDSCAPE 171
12.1 OVERVIEW 171
12.2 MARKET SHARE ANALYSIS 171
12.3 COMPETITIVE SITUATION AND TRENDS 173
12.3.1 AGREEMENTS, COLLABORATIONS, & PARTNERSHIPS 174
12.3.2 REGULATORY APPROVALS 174
12.3.3 ACQUISITIONS 175
12.3.4 OTHER DEVELOPMENTS 176
13 COMPANY PROFILES 177
13.1 INTRODUCTION 177
13.2 GLAXOSMITHKLINE, PLC. 178
13.3 MERCK & CO., INC. 181
13.4 SANOFI PASTEUR 184
13.5 PFIZER, INC. 187
13.6 NOVARTIS AG 189
13.7 BAVARIAN NORDIC 192
13.8 CSL LIMITED 194
13.9 EMERGENT BIOSOLUTIONS, INC. 196
13.10 JOHNSON & JOHNSON 198
13.11 MEDIMMUNE, LLC. (A SUBSIDIARY OF ASTRAZENECA) 200
*Details On Financials, Products & Services, Key Strategy, & Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
14 APPENDIX 202
14.1 RECENT DEVELOPMENTS 202
14.1.1 GLAXOSMITHKLINE, PLC. 202
14.1.2 SANOFI PASTEUR 203
14.1.3 NOVARTIS AG 204
14.1.4 EMERGENT BIOSOLUTIONS INC. 204
14.2 INSIGHTS FROM INDUSTRY EXPERTS 205
14.3 DISCUSSION GUIDE 206
14.4 AVAILABLE CUSTOMIZATIONS 208
14.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 209
14.6 RELATED REPORTS 210